Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD137/PD-L1 bispecific monoclonal antibody FS222

A tetravalent immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-CD137/PD-L1 bispecific antibody FS222 simultaneously targets and binds to CD137, which is expressed on a variety of leukocyte subsets including activated T lymphocytes, and PD-L1 expressed on tumor cells, thereby crosslinking PD-L1-expressing tumor cells and T lymphocytes. Through CD137 binding, FS222 acts as a conditional CD137 agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, FS222 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T cells inhibits the expansion and survival of CD8-positive T cells, suppresses the immune system and results in immune evasion. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. Crosslinking of PD-L1-expressing tumor cells and activated T lymphocytes may enhance T-lymphocyte-mediated lysis of PD-L1-expressing tumor cells.
Synonym:anti-CD137/anti-PD-L1 bispecific antibody FS222
anti-PD-L1/anti-4-1BB bispecific antibody FS222
CD137xPD-L1 bispecific antibody FS222
Code name:FS 222
FS-222
FS222
Search NCI's Drug Dictionary